SDSanjay Das

Sanjay Das

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sanjay Das has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Contemporary risk of biochemical recurrence after radical prostatectomy in the active surveillance era

    by Sanjay Das, Michael Luu, Martha Terris, Zachary Klaassen, Christopher J. Kane, Christopher Amling, Matthew Cooperberg, Lourdes Guerrios Rivera, William Aronson, Stephen J. Freedland, et al.


  • Relative search popularity of five advanced prostate cancer medications using Google Trends

    by Sanjay Das, Nadine A. Friedrich, James Daniels, G. Cecilia Galvan, Jun Gong, Edwin Posadas, William Aronson, Stephen J. Freedland

    Background There are many FDA-approved drugs for advanced prostate cancer (PC), yet public interest in these drugs is not well understood. We compared public interest and state-level predictors of interest in five common oral adjunctive hormonal therapies. Methods Google Trends™ was queried for: “Enzalutamide”, “Abiraterone Acetate”, “Bicalutamide”, “Apalutamide”, and “Darolutamide” in the United States from January 2004 to November 2022. Data are presented as relative search index (RSI) by month. RSI ranges from 0 to 100 with 100 being peak popularity, 50 being half of the peak popularity, and 0 representing insufficient data to be determined. Results Several drugs abruptly increased in popularity following FDA approval including abiraterone, enzalutamide, and apalutamide. All drugs decreased in popularity from January 2020 to July 2020, corresponding with the COVID-19 pandemic. In the most recent 5 years, enzalutamide and abiraterone were the most common searched drugs, with bicalutamide a close 3rd place. States that did not expand Medicaid were significantly more likely to have bicalutamide as the top search drug vs. states that expanded Medicaid (p = 0.012). Across all states with data (n = 39), higher bicalutamide RSIs were significantly associated with lower household income (r = 0.385, p = 0.02) and greater percent of uninsured adults (r = 0.426, p = 0.007). This is the first study using Google Trends to compare advanced PC drugs by search popularity. Conclusions Despite the emergence of more effective medications, bicalutamide remains relatively popular, particularly in states with lower household income, more uninsured adults, or those that did not expand Medicaid, possibly due to its lower cost.


  • Open Access

    Investigating trends in interest for benign prostatic hyperplasia surgery options using Google Trends

    by James P. Daniels, Devin N. Patel, Gloria Cecilia Galvan, Nadine A. Friedrich, Sanjay Das, Arash Akhavein, Timothy Daskivich, David Josephson, Premal Desai, Cosimo De Nunzio, et al.

    Understanding patient interest among surgical options is challenging. We used Google Trends to analyze interest in benign prostatic hyperplasia (BPH) surgeries recommended for prostate volumes <80 cc. Google Trends was queried with five BPH surgeries. Final rank of search terms was TURP, UroLift, Rezum, Aquablation, and Greenlight. Google Trends can be an effective tool for evaluating public interest trends in BPH surgery.


  • The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence

    by Sanjay Das, Lin Gu, Claire Trustram Eve, Joshua Parrish, Amanda M. De Hoedt, Chad McKee, William Aronson, Stephen J. Freedland, Stephen B. Williams


  • Statins and Cancer Prevention—Association Does Not Mean Causation

    by Sanjay Das, Stephen J. Freedland

    Statins are widely prescribed medications that inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG CoA) reductase and therefore reduce cholesterol synthesis. Given the key role of cholesterol in cancer, statins may therefore have anticancer activities. However, clinical studies investigating the association between statin usage and cancer development have been few and inconsistent. A recent study from Maeda-Minami and colleagues found a significant, though modest, decrease in cancer risk among statin users. However, does this finding mean statin usage directly reduces cancer risk or is merely associated with reduced cancer risk? This editorial analyzes Maeda-Minami and colleagues’ study to provide commentary on statin's proposed role in preventing cancer. See related article, p. 37


  • Mental health implications in urologic cancer hospitalizations.

    by Sanjay Das, Sai Srikar Kilaru, Beth Bailey

    74 Background: Increased mortality from urologic cancers coupled with an aging population has resulted in patient care becoming more specialized to improve patient outcomes. Though family history, lifestyle behaviors, and genetics are all used to determine risk and treatment, there is a knowledge gap of whether mental illness (MI) should also be considered. Therefore, this study seeks to determine whether hospitalizations of urologic cancers plus MIs are associated with increased all-cause mortality, length of hospital stay (LOS), costs of hospitalization and nosocomial infection rates. Methods: Inpatient data from 2016-2017 was obtained from the National Inpatient Sample database. This included all hospitalizations with at least one diagnosis of urologic cancer including prostate, bladder, kidney, renal pelvis, ureteral, urethral, testicular, and penile cancers. MIs of interest were depression, anxiety, substance abuse, and schizophrenia and related disorders. Data analysis and regression models were performed using SPSS Statistics. Reported odds ratios and significance values were controlled for Age, Sex, Income, Race, Insurance, Location, Mortality Risk, and Illness Severity. Results: There were 146,706 hospitalizations involving urologic cancers between 2016-2017. For these hospitalizations, depression and anxiety were associated with a decreased likelihood of death, and all MIs were associated with increased LOS. For hospitalizations involving prostate cancer, Depression and Substance Abuse were associated with decreased likelihood of death (all-causes). Hospitalizations involving kidney cancer had increased total charges and increased LOS. Hospitalizations involving bladder cancer were associated with decreased likelihood of death, and increased LOS for all MIs except, notably, those with substance abuse. Penile Cancer hospitalizations coded for anxiety showed increased LOS, and testicular cancer hospitalizations coded for substance abuse had increased likelihood of death. Conclusions: MIs can affect hospitalization outcomes of patients with urologic cancer differently based on the type of urologic cancer. Interestingly, our analysis showed that Depression was associated a decreased likelihood of death in hospitalizations coded for Prostate Cancer and Bladder Cancer. Though unexpected, we hypothesize that this finding may be partially due to implicit bias from healthcare providers that lead to enhanced care (e.g. increased patient monitoring, better support from auxiliary units such as Social Work). However, there is an absence of research in substantiating this claim. Further research is warranted to better assess the effect of Depression on the mortality of Urologic Cancer patients, and on how to best incorporate mental health status in the overall management of these patients.

  • Initial Findings from a High Genetic Risk Prostate Cancer Clinic

    by Michael S. Sessine, Sanjay Das, Bumsoo Park, Simpa S. Salami, Samuel D. Kaffenberger, Amy Kasputis, Marissa Solorzano, Mallory Luke, Randy A. Vince, Deborah R. Kaye, et al.